BGPT: Author Review: Hwangseo Park

Explore by Goal

Quick Explanation Copied

Author snapshot — Hwangseo Park

Representative papers and metrics indicate research in computational chemistry / drug discovery and structure-based virtual screening (example: Bioorg. Med. Chem. Lett. 2009) and cell biology / autophagy (example: Sci. Rep. 2016); citation patterns show multi-decade activity with several well-cited works (see long review for year-by-year plot and critical appraisal).

Representative sources: BMCL 2009 Hsp90 screening (DOI:10.1016/j.bmcl.2009.06.040) • Sci. Rep. 2016 (DOI:10.1038/srep21772)

Long Explanation

Author Review: Hwangseo Park — Visual, critical, evidence‑based

Key empirical facts (evidence links)

Representative experimental/computational work: structure-based virtual screening identifying Hsp90 inhibitors; MD refinement and short in vitro validation reported (IC50s in tens of μM; BMCL 2009) (DOI:10.1016/j.bmcl.2009.06.040).
Examples of later, higher-citation works in the author network: contribution as co-author to a 2016 Scientific Reports paper on resveratrol and mTOR/autophagy (DOI:10.1038/srep21772) with high citation count, showing collaborations in cell‑biology and pharmacology contexts (DOI:10.1038/srep21772).

Critical appraisal — strengths and limitations

Strengths — demonstrated competence in structure-based docking and MD workflows with experimental follow-up (BMCL 2009); participation in interdisciplinary projects that produced high-impact, well-cited outputs (Sci. Rep. 2016). The publication mix includes computational chemistry, medicinal chemistry, and some experimental validation — a positive sign of cross-disciplinary capability.

Limitations / red flags — for the BMCL 2009 work: low in vitro potency relative to benchmarks (gedanamycin), tiny assay sample sizes (n=2 reported for IC50/GI50), short MD (1 ns) that may not capture relevant conformational sampling, and lack of in vivo or selectivity/toxicity profiling; these limit translational confidence and robustness of SAR conclusions. These are standard caveats for early-stage virtual screening papers but must be weighed when judging overall scientific rigor.

Citation/impact pattern — the author (as represented in OpenAlex records aggregated for the same name) appears in both modestly cited papers and some high‑impact collaborations; citation spikes in mid‑2000s and 2010s indicate contributions to widely used computational methods and drug‑discovery reports (see plotted time-series above). High-citation individual works suggest strong collaborative contributions even if some first‑author outputs are fewer or less cited.

What this implies about scientific strength

Technical competency: demonstrated (docking, MD, biochemical assays) — good foundation for computational drug-discovery work (BMCL 2009).
Reproducibility & rigor: mixed — methods described, but small n and short MD reduce statistical and dynamical robustness; follow-up work, larger replicates, longer MD, and orthogonal assays would strengthen claims.
Impact: variable — some first-author papers modestly cited; coauthorship on higher-cited works indicates effective collaboration and contributions to influential studies.

Practical suggestions to improve scientific profile (concise)

Increase replicate counts and report full assay variance/confidence intervals for bioassays.
Use longer MD (tens–hundreds ns) or enhanced-sampling to validate docking poses and water-mediated interactions.
Provide selectivity/toxicity panels and, where relevant, orthogonal biophysical binding evidence (ITC, SPR) and in vivo validation for leads.
Disambiguate author name across databases; ensure ORCID and institutional affiliations are linked to improve attribution and metric accuracy.

Feedback:

Updated: March 17, 2026